In patients with chronic myeloid leukaemia SLC22A1 expression is associated with treatment response to the tyrosine kinase inhibitor (TKI) imatinib [13,22,29]. This evidence concerns the gene SLC22A1 and chronic myelogenous leukemia, BCR-ABL1 positive.